# Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19

> **NCT01864889** · NA · UNKNOWN · sponsor: **Chinese PLA General Hospital** · enrollment: 12 (estimated)

## Conditions studied

- Hematopoietic/Lymphoid Cancer
- Adult Acute Lymphoblastic Leukemia in Remission
- B-cell Adult Acute Lymphoblastic Leukemia
- B-cell Chronic Lymphocytic Leukemia
- Prolymphocytic Leukemia
- Recurrent Adult Diffuse Large Cell Lymphoma
- Recurrent Grade 1 Follicular Lymphoma
- Recurrent Grade 2 Follicular Lymphoma
- Recurrent Grade 3 Follicular Lymphoma
- Recurrent Mantle Cell Lymphoma
- Refractory Chronic Lymphocytic Leukemia
- Stage III Adult Diffuse Large Cell Lymphoma
- Stage III Chronic Lymphocytic Leukemia
- Stage III Grade 1 Follicular Lymphoma
- Stage III Grade 2 Follicular Lymphoma
- Stage III Grade 3 Follicular Lymphoma
- Stage III Mantle Cell Lymphoma
- Stage IV Adult Diffuse Large Cell Lymphoma
- Stage IV Chronic Lymphocytic Leukemia
- Stage IV Grade 1 Follicular Lymphoma
- Stage IV Grade 2 Follicular Lymphoma
- Stage IV Grade 3 Follicular Lymphoma
- Stage IV Mantle Cell Lymphoma

## Interventions

- **BIOLOGICAL:** anti-CD19-CAR vector-transduced T cells

## Key facts

- **NCT ID:** NCT01864889
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-04
- **Primary completion:** 2017-04
- **Final completion:** 2017-04
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2016-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01864889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01864889, "Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01864889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*